Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?

Regulatory Peptides

Volumn 183, Issue 1, 2013, Pages 54-61

  Daousi, Christina ^a   Pinkney, Jonathan H ^b   Cleator, Jacqueline ^a   Wilding, John P ^a   Ranganath, L R ^c  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Adiponectin; Ghrelin; IL 6; Incretins; Leptin; Obestatin

Indexed keywords

ADIPONECTIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN; INTERLEUKIN 6; LEPTIN; OBESTATIN; PLACEBO; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; PEPTIDE FRAGMENT;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; PEPTIDE FRAGMENTS;

EID: 84875779296     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.03.004     Document Type: Article

References (30)

1. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004, 287:E199-E206.
2. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
3. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino Y., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007, 117:143-152.
4. Yamada Y., Miyawaki K., Tsukiyama K., Harada N., Yamada C., Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 2006, 55:S86-S91.
5. Hagemann D., Holst J.J., Gethmann A., Banasch M., Schmidt W.E., Meier J.J. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 2007, 143:64-68.
6. Lacquaniti A., Donato V., Chirico V., Buemi A., Buemi M. Obestatin: an interesting but controversial gut hormone. Ann Nutr Metab 2011, 59:193-199.
7. Daousi C., Wilding J.P., Aditya S., Durham B.H., Cleator J., Pinkney J.H., et al. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 2009, 71:195-201.
8. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993, 76:912-917.
9. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
10. Meier J.J., Nauck M.A., Schmidt W.E., Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002, 107:1-13.
11. Meier J.J., Gallwitz B., Siepmann N., Holst J.J., Deacon C.F., Schmidt W.E., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
12. Kim Chung lT, Hosaka T., Yoshida M., Harada N., Sakaue H., Sakai T., et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009, 390:613-618.
13. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316:129-139.
14. Sam S., Haffner S., Davidson M.H., D'Agostino R.B., Feinstein S., Kondos G., et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009, 32:932-937.
15. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
16. van Hall G., Steensberg A., Sacchetti M., Fischer C., Keller C., Schjerling P., et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003, 88:3005-3010.
17. Feve B., Bastard J.P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:305-311.
18. Devaraj S., Dasu M.R., Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010, 5:19-28.
19. Courreges J.P., Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008, 25:1129-1131.
20. Bunck M.C., Corner A., Eliasson B., Heine R.J., Shaginian R.M., Wu Y., et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010, 212:223-229.
21. Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51:1584-1592.
22. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010, 11:430-445.
23. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010, 21:261-267.
24. Vilsboll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009, 11:11-18.
25. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
26. Perez-Tilve D., Gonzalez-Matias L., varez-Crespo M., Leiras R., Tovar S., Dieguez C., et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56:143-151.
27. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50:1714-1719.
28. Djurhuus C.B., Hansen T.K., Gravholt C., Orskov L., Hosoda H., Kangawa K., et al. Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res 2002, 34:411-413.
29. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
30. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.